Table 2.
Immunophenotype of primary patient samples and corresponding cell lines.
| Antibody | Patients and Corresponding Cell Lines | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P272 | PER-494 | P272 at Relapse | PER-485 | P287 | PER-490 | P337 | PER-784 | PER-826 | P399 | PER-785 | P810 | PER-703 | P899 | PER-910 | |
| CD1a | 0% | 0% | 0% | 0% | 0% | 0% | <1% | 0% | |||||||
| CD2 | 7% | <1% | 8% | <1% | 3% | <1% | <1% | <1% | <1% | <1% | <1% | 4% | <1% | <1% | |
| iCD3 | <1% | <1% | <1% | <1% | <1% | <1% | <1% | <1% | <1% | <1% | |||||
| CD3 | 8% | <1% | 7% | <1% | 3% | <1% | 1% | <1% | <1% | <1% | 1% | 4% | <1% | <1% | |
| CD4 | <1% | 100% | 2% | <1% | <1% | 28% | 99% | <1% | |||||||
| CD5 | 7% | 1% | 6% | <1% | 3% | <1% | <1% | <1% | <1% | <1% | 8% | 2% | 2% | <1% | |
| CD7 | 6% | <1% | <1% | 3% | <1% | 14% | 1% | 99% | 1% | 37% | 13% | <1% | 11% | 23% | |
| CD8 | <1% | <1% | <1% | <1% | <1% | 1% | 98% | <1% | |||||||
| CD10 | 84% | 100% | 7% | 4% | 0% | <1% | <1% | 10% | 1% | <1% | <1% | 3% | 29% | 25% | 6% |
| CD11b | 19% | 65% | 30% | 3% | 4% | 14% | 100% | <1% | |||||||
| CD11c | 17% | 60% | 39% | 1% | 24% | 3% | 57% | <1% | |||||||
| CD13 | 0% | 16% | 57% | 31% | 7% | 99% | 1% | 5% | 10% | 74% | 65% | 44% | 1% | ||
| CD14 | <1% | 11% | 7% | <1% | <1% | <1% | <1% | 100% | <1% | ||||||
| CD15 | <1% | 11% | 100% | 47% | 99% | <1% | <1% | 29% | 100% | <1% | |||||
| CD19 | 90% | 100% | 69% | <1% | 72% | 100% | 98% | 98% | 99% | 99% | 100% | 95% | <1% | 96% | 99% |
| CD20 | <1% | <1% | <1% | 6% | <1% | <1% | < 1% | <1% | <1% | <1% | |||||
| iCD22 | <1% | <1% | <1% | <1% | <1% | <1% | <1% | <1% | |||||||
| CD22 | <1% | <1% | <1% | <1% | <1% | <1% | <1% | <1% | |||||||
| CD24 | 90% | 100% | 100% | 11% | 100% | < 1% | 100% | 99% | 48% | 100% | 87% | 100% | 94% | ||
| CD33 | 0% | 4% | 66% | 99% | 77% | 23% | 16% | 20% | 50% | 17% | 58% | 100% | 1% | 6% | |
| CD34 | 94% | <1% | 67% | <1% | 21% | <1% | 66% | <1% | <1% | 98% | <1% | 2% | <1% | 2% | <1% |
| CD38 | 98% | <1% | 71% | 97% | 100% | 80% | 96% | 99% | 99% | ||||||
| CD45 | 96% | 99% | 1% | 100% | 68% | 100% | 100% | 100% | 100% | 99% | |||||
| CD64 | 12% | 17% | 11% | 2% | 9% | 20% | 1% | 100% | <1% | ||||||
| CD65 | <1% | 86% | 66% | <1% | <1% | 13% | 96% | <1% | |||||||
| iCD79a | 73% | <1% | 88% | 79% | 94% | 83% | 98% | <1% | 99% | 90% | |||||
| CD117 | 0% | 0% | 0% | 0% | 0% | 0% | <1% | 0% | 3% | 0% | |||||
| HLA-DR | 86% | 99% | 6% | 80% | 100% | 100% | 100% | 100% | 42% | 95% | 96% | 100% | |||
| iLysozyme | 0% | 1% | 0% | 0% | 0% | 0% | <1% | 0% | |||||||
| iMPO | <1% | 2% | <1% | <1% | <1% | 0% | 1% | 24% | <1% | <1% | |||||
| iIgM | <1% | <1% | <1% | <1% | <1% | <1% | 49% | 2% | 97% | <1% | |||||
| IgM | 1% | <1% | 23% | <1% | <1% | 6% | <1% | <1% | 2% | <1% | 12% | 2% | |||
| iTDT | <1% | <1% | <1% | 15% | <1% | <1% | 98% | 1% | 6% | <1% | <1% | <1% | |||